{
    "clinical_study": {
        "@rank": "33578", 
        "arm_group": [
            {
                "arm_group_label": "exforge 10/160mg(amlodipine 10mg, valsartan160mg)", 
                "arm_group_type": "Experimental", 
                "description": "1 tablet daily for 10days"
            }, 
            {
                "arm_group_label": "crestor 20mg(rosuvastatin 20mg)", 
                "arm_group_type": "Experimental", 
                "description": "1 tablet daily for 7days"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designated to evaluate the pharmacokinetic interactions of amlodipine\n      besylate, valsartan and rosuvastatin in healthy male volunteers."
        }, 
        "brief_title": "A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male volunteers in the age between 20 and 55 years old\n\n          2. The weight range is not exceed \u00b120% of ideal weight Ideal weight = [height -100]*0.9\n\n          3. Subjects with no history of any significant chronic disease\n\n          4. Judged to be in good health on the basis of their electrocardiography (ECG) and\n             routine laboratory data obtained within 3 weeks prior to study drug administration\n\n          5. Willing to adhere to protocol requirements and sign a informed consent form\n\n        Exclusion Criteria:\n\n          1. History of clinically significant allergies including drug allergies\n\n          2. History of clinically significant hepatic, renal, gastrointestinal, pulmonary,\n             ,musculoskeletal, endocrine, psychiatric, hematologic, oncologic, neurologic or\n             cardiovascular disease\n\n          3. History of genetic muscluar disease and family history\n\n          4. hyotension (Systolic Blood Pressure(SBP) \u2264 105 or Diastolic Blood Pressure(DBP) \u2264 65)\n             or hypertension(SBP \u2265 150 or DBP \u2265 100)\n\n          5. AST(Aspartate Transaminase), ALT(ALanine Transaminase), total bilirubin( > 1.5 times\n             to normal range\n\n          6. Creatinine clearance < 80mL/min\n\n          7. Subjects with a history of gastrointestinal diseases which might significantly change\n             ADME(Absorption, Distribution, Metabolism and Excretion) of medicines\n\n          8. Serious injury, surjery and acute illness within 4 weeks prior to drug administration\n\n          9. History of alcohol, smoking abuse\n\n               -  alcohol > 21 units/week, 1 unit=10g=12.5mL of pure alcohol\n\n               -  smoking > 10 cigarettes/day\n\n         10. Use of any other medication, including herbal products, within the 2 weeks before\n             dosing\n\n         11. Participated in a previous clinical trial within 3 months prior to drug\n             administration\n\n         12. Subjects with whole blood donation within 2 months, component blood donation within\n             months prior to drug administration\n\n         13. Special diet known to interfere with the absorption, distribution, metabolism or\n             excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior\n             to drug administration\n\n         14. Clinical laboratory test values are positive (HBsAg, HCV Ab, HIV Ag/Ab, VDRL)\n\n         15. Subjects considered as unsuitable based on medical judgement by investigators"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060019", 
            "org_study_id": "CJ_EXR_101"
        }, 
        "intervention": {
            "arm_group_label": [
                "exforge 10/160mg(amlodipine 10mg, valsartan160mg)", 
                "crestor 20mg(rosuvastatin 20mg)"
            ], 
            "intervention_name": "administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Rosuvastatin", 
                "Amlodipine, valsartan drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pharmacokinetics", 
            "Pharmacodynamics", 
            "Safety", 
            "Tolerability"
        ], 
        "lastchanged_date": "February 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Deagu", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Kyungpook university hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects", 
        "overall_contact": {
            "email": "kssong1212@cj.net", 
            "last_name": "Geun-Seog Song, PhD", 
            "phone": "82-2-6740-2440"
        }, 
        "overall_contact_backup": {
            "email": "keunji@cj.net", 
            "last_name": "Eun-Ji Kim", 
            "phone": "82-2-6740-2443"
        }, 
        "overall_official": {
            "affiliation": "Kyungpook university hostipal", 
            "last_name": "Young Ran Yoon PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "after steady state (Administration of Investigational Product 7day or 10days)", 
            "measure": "Assessment of the drug-drug interactions of amlodipine, valsartan and rosuvastatin: Cmax,ss(Maximum steady-state plasma drug concentration during a dosage interval ), AUC\u03c4(Area Under the Curve)", 
            "safety_issue": "No", 
            "time_frame": "3 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060019"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "steady state (Administration of Investigational Product)", 
            "measure": "Assessment of the amlodipine, valsartan and rosuvastatin : AUCinf, tmax,ss(Time to reach Cmax,ss), t1/2", 
            "safety_issue": "No", 
            "time_frame": "3 days"
        }, 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}